Akihiro Goriki

Dr. Akihiro Goriki


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
YKYuki Kohada
Yuki Kohada
KGKeisuke Goto
Keisuke Goto
RTRyo Tasaka
Ryo Tasaka
KNKensuke Nishida
Kensuke Nishida
KHKunihiro Hashimoto
Kunihiro Hashimoto
NHNobuyki Hinata
Nobuyki Hinata

24 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KMKoji Mita
Koji Mita
KIKouji Izumi
Kouji Izumi
AGAkihiro Goriki
Akihiro Goriki
RTRyo Tasaka
Ryo Tasaka
THTomoya Hatayama
Tomoya Hatayama
AMAtsushi Mizokami
Atsushi Mizokami
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for CRPC, an investigator-initiated, multicenter, randomized controlled trial (ENABLE Study for PCa) including both metastatic and nonmetastatic CRPC was conducted in Japan. The prostate-specific antigen (PSA) response rate, overall survival, some essential survival endpoints, and safety of patients with nonmetastatic CRPC were also analyzed. In this subanalysis, 15 and 26 patients in the ENZ and ABI arms, respectively, presented with nonmetastatic CRPC. There was no significant difference in terms of the PSA response rate between the ENZ and ABI arms (80% and 64%, respectively; p = 0.3048). The overall survival did not significantly differ between the two arms (HR: 0.68; 95% CI: 0.22–2.14, p = 0.5260). No significant differences were observed in terms of radiographic progression-free survival and cancer-specific survival between the ENZ and ABI arms (HR: 0.81; 95% CI: 0.35–1.84; p = 0.6056 and HR: 0.72; 95% CI: 0.19–2.73; p = 0.6443, respectively). Only four and six patients in the ENZ and ABI arms, respectively, had ≥grade 3 adverse events. ABI and ENZ had similar efficacy and safety profiles in patients with nonmetastatic CRPC.

20 February 2025 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
THTomoya Hatayama
Tomoya Hatayama
KGKeisuke Goto
Keisuke Goto
YKYuki Kohada
Yuki Kohada
KNKensuke Nishida
Kensuke Nishida
TUTakeshi Ueno
Takeshi Ueno
NHNobuyki Hinata
Nobuyki Hinata
Purpose: We aimed to evaluate the ability of the advanced lung cancer inflammation index (ALI) to predict the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). We also aimed to compare the ALI with other inflammatory or nutritional indices as prognostic indicators. Methods: We retrospectively evaluated patients who underwent RNU for UTUC at multiple centers between January 2010 and April 2024. We calculated the ALI before RNU and divided the patients into the low ALI and high ALI groups. We used 1:1 propensity score matching (PSM) to adjust the clinicopathological differences between two groups. We compared the overall survival (OS) and recurrence-free survival (RFS) of the low and high ALI groups using the Kaplan-Meier method. Furthermore, we assessed the ALI as a predictor of OS and RFS using a multivariate Cox proportional hazards regression analysis. Results: Of 488 patients (48.3% low ALI group), 160 patients from each group were matched. The Kaplan-Meier analysis revealed that the OS ( p = 0.009) and RFS ( p = 0.006) of the low ALI group were significantly shorter than those of the high ALI group. According to a multivariate analysis that included clinicopathological prognostic indicators, a low ALI was an independent predictor of poor OS ( p = 0.014) and RFS ( p = 0.038). Furthermore, according to the multivariate analysis including other inflammatory or nutritional indices, the ALI was an independent predictor of poor OS ( p = 0.024) and RFS ( p = 0.044). Conclusions: The ALI was a significantly useful prognostic predictors of patients with UTUC who underwent RNU.

9 October 2024 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
KKKohei Kobatake
Kohei Kobatake
KGKeisuke Goto
Keisuke Goto
YHYukiko Honda
Yukiko Honda
MNMiki Naito
Miki Naito
KTKenshiro Takemoto
Kenshiro Takemoto
NHNobuyki Hinata
Nobuyki Hinata
Purpose: Positive surgical margins (PSM) after robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa) can increase the risk of biochemical recurrence and PCa-specific mortality. We aimed to evaluate the impact of multidisciplinary team meetings (MDTM) on reducing the incidence of PSM following RARP. Methods: We retrospectively collected the clinical data of consecutive patients undergoing RARP at Hiroshima University between February 2017 and October 2023. The MDTM, comprising a radiologist, uropathologist, and urologist, reviewed the preoperative magnetic resonance imaging (MRI) and prostate biopsy results of each patient before RARP and considered the areas requiring attention during RARP. Surgeons were categorized as experienced or non-experienced based on the number of RARP procedures performed. Results: In the pT2 population, the PSM rate was significantly lower in cases evaluated using the MDTM than in those not (11.1% vs. 24.0%; p = 0.0067). Cox regression analysis identified that a PSA level > 7 ng/mL (hazard ratio 2.2799) and nerve-sparing procedures (hazard ratio 2.2619) were independent predictors of increased PSM risk while conducting an MDTM (hazard ratio 0.4773) was an independent predictor of reduced PSM risk in the pT2 population. In the pathological T3 population, there was no significant difference in PSM rates between cases evaluated and not evaluated at an MDTM. In cases evaluated at an MDTM, similar PSM rates were observed regardless of surgeon experience (10.4% for non-experienced and 11.9% for experienced surgeons; p = 0.9999). Conclusions: An MDTM can improve the PSM rate of pT2 PCa following RARP.

1 January 2025 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
THTomoya Hatayama
Tomoya Hatayama
KMKoji Mita
Koji Mita
YKYuki Kohada
Yuki Kohada
KFKenta Fujiyama
Kenta Fujiyama
RTRyo Tasaka
Ryo Tasaka
NHNobuyki Hinata
Nobuyki Hinata
Hatayama T, et al. Investig Clin Urol. 2025 Feb;66:e14. https://doi.org/10.4111/icu.20240357

22 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Sekino YoheiSekino Yohei
Sekino Yohei
HNHikaru Nakahara
Hikaru Nakahara
KIKenichiro Ikeda
Kenichiro Ikeda
KKKohei Kobatake
Kohei Kobatake
YKYuki Kohada
Yuki Kohada
NHNobuyki Hinata
Nobuyki Hinata
Background/Objectives: It is said that genes that escape from X chromosome inactivation (XCI) contribute to gender differences. We analyzed the prognostic role of these genes and identified a gender-biased difference in prognosis according to KDM6A mutation in the immune therapy cohort (IMvigor 210). We also investigate the gender-biased differential effect of KDM6A mutation in several public databases of urothelial carcinoma (UC). Methods: We used AACR GENIE, The Cancer Genome Atlas, International Cancer Genome Consortium, several public databases related to immune therapy, chemotherapy, and BCG treatment. We studied the gender-biased prognostic role of KDM6A mutation in several cohorts and the association between KDM6A mutation and immune-related fractions according to gender. Results: The expression of KDM6A was higher in females than in males in several cohorts. Mutation of KDM6A was observed in about 20–25% of the patients. The rate of KDM6A mutation was higher in females than in males in several cohorts. Kaplan–Meier analysis revealed a gender-biased difference in prognosis between patients with KDM6A mutations and those with the wild-type KDM6A in several cohorts, including the immune therapy cohort. The rate of immune-inflamed type was higher in males than in females in the patients with KDM6A mutation in the IMvigor 210 and UC-GENOME studies. Single-sample Gene Set Enrichment Analysis showed that CD8+ cells and type 1 IFN response fractions and APC co-inhibition fraction were higher in the male than female patients with KDM6A mutation. Similar findings were observed in other immune-related studies (UC-GENOME). Conclusions: The effect of KDM6A mutation on immune therapy varied according to gender, and the status of KDM6A mutation may be a promising biomarker in immune therapy in UC.